Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Phenobarbital for Alcohol Withdrawal

Introduction to Alcohol Withdrawal Management

  • Benzodiazepines are the gold standard for alcohol withdrawal management because they alleviate withdrawal discomfort, prevent seizures, and reduce the risk of delirium tremens through GABA receptor activation, according to the American College of Physicians 1, 2, 5.
  • The American Academy of Family Physicians recommends benzodiazepines as first-line treatment for alcohol withdrawal, with long-acting agents preferred for most patients without liver disease due to superior seizure and delirium tremens protection 3, 4.

Pharmacological Interventions

  • The American College of Cardiology is not directly involved, but the general medical consensus, as reported in PLoS Medicine, supports the use of benzodiazepines, with lorazepam preferred for patients with cirrhosis, advanced age, or serious medical comorbidities to avoid drug accumulation 4.
  • Phenobarbital should be considered as an effective alternative that may reduce hospital length of stay and is particularly valuable when benzodiazepines fail to control withdrawal symptoms, as suggested by the clinical guidelines summarized in Praxis Medical Insights 4.

Essential Adjunctive Treatments

  • All patients must receive thiamine 100-300 mg/day to prevent Wernicke encephalopathy, administered BEFORE any glucose-containing IV fluids, as recommended by the National Institute of Health 3, 4.
  • High-risk patients require parenteral thiamine, and thiamine should be continued for 2-3 months after symptom resolution, according to the guidelines from the American Medical Association 1, 2, 5, 3, 4.

Monitoring and Safety

  • The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores should be used to guide treatment intensity, with scores >8 indicating moderate withdrawal requiring pharmacological intervention, and scores ≥15 indicating severe withdrawal requiring aggressive treatment, as advised by the Substance Abuse and Mental Health Services Administration 3, 4.
  • Patients at risk of severe withdrawal or with serious comorbidities should be managed in an inpatient setting, as recommended by the American Hospital Association 1, 2, 5, 3.